August 1, 2003Expert Opinion on Therapeutic Patents
Update on GPIIb/IIIa antagonists
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Ongoing patent activity signals continued interest in GPIIb/IIIa antagonists; leaves open whether new agents will overcome prior clinical failures.
Structured PICO
I
Intervention
GPIIb/IIIa antagonists (review of 16 patents and >40 molecules)
Despite previous disappointing clinical results with oral agents, research continues into developing new orally-active GPIIb/IIIa antagonists with better binding profiles.
Cite This Study
Hanson et al. (2003) studied this question.